Astrana Health (NASDAQ:ASTH) Announces Earnings Results, Misses Estimates By $0.09 EPS

Astrana Health (NASDAQ:ASTH - Get Free Report) issued its quarterly earnings data on Thursday, May 8th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.09), Zacks reports. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $620.39 million for the quarter, compared to the consensus estimate of $628.11 million. During the same period in the prior year, the company posted $0.31 earnings per share. Astrana Health's quarterly revenue was up 53.4% compared to the same quarter last year. Astrana Health updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Astrana Health Stock Down 3.9%

Astrana Health stock traded down $1.03 during midday trading on Thursday, hitting $25.48. The stock had a trading volume of 42,769 shares, compared to its average volume of 285,721. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a market cap of $1.43 billion, a P/E ratio of 19.62, a P/E/G ratio of 1.37 and a beta of 1.00. Astrana Health has a 12 month low of $23.12 and a 12 month high of $63.20. The business has a fifty day moving average price of $30.86 and a 200 day moving average price of $35.82.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Robert W. Baird dropped their price objective on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Barclays started coverage on shares of Astrana Health in a report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price target on the stock. Stifel Nicolaus reduced their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Bank of America reduced their target price on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Finally, Truist Financial reduced their target price on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $53.29.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.